
December 06, 2024
Merissa Hawkins
Categories:
Articles
Share with your network
Despite the dedicated efforts of healthcare providers, the prevalence of obesity in the U.S. increased from 30.5% in 2000 to 41.9% in 2020. Obesity-related conditions (including heart disease, certain cancers, and type 2 diabetes) remain the leading causes of preventable death and place a significant financial burden on the U.S. healthcare system, costing over $173 billion annually.
The introduction of GLP-1 medications, like Ozempic and Wegovy, offers hope for long-term population health improvements. However, the surging demand for these medications is creating a significant strain on employers, with skyrocketing costs becoming an immediate challenge.
At Amino Health, we provide Intelligent Routing for GLP-1s to help employers manage these rising costs while empowering members with effective care solutions.
How It Works:
Why This Matters:
Let’s Build Smarter Care Together
Amino Health is your partner in navigating the complexities of GLP-1 management. With tailored search and support, we ensure members have easy access to affordable, high-quality care.
Want to learn how we can help your members transform their healthcare experience in 2025?
Copyright © Amino Health Inc. 2025
Amino Health does not endorse or guarantee, and disclaims any liability for any of the information, recommendations, programs, products, or services advertised, offered by, or made available by any third party or through any external website referenced or linked herein.